Verastem reports 42% ORR in FRAME study for avutometinib/defactinib in LGSOC

Verastem, Inc.

Overall response rate 42% (11/26) in evaluable recurrent LGSOC patients.
ORR 58% in KRAS mutant LGSOC (7/12) vs 33% in KRAS wild-type (4/12).
Median duration of response 26.9 months; median PFS 20.0 months.
19% of patients (5/26) remained on treatment at data cutoff, minimum 17 months follow-up.
RAMP 201 Part A confirmed 45% ORR by independent review reported at ASCO 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.